We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In an unusual move, Celgene has backed out of a $55 million settlement to clear accusations of anticompetitive behavior over its cancer treatments Revlimid and Thalomid, attorneys for the plaintiffs announced Wednesday. Read More
The Federal Circuit Court of Appeals gave Amgen another chance to prove that Amneal’s planned generic of its hyperparathyroidism treatment Sensipar (cinacalcet) infringes on its patent. Read More